The University of Chicago Header Logo

Connection

Michael Charlton to Hepacivirus

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Hepacivirus.
Michael Charlton
Connection Strength
4.073
Hepacivirus
  1. Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med. 2016 04 28; 374(17):1688.
    View in: PubMed
    Score: 0.509
  2. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View in: PubMed
    Score: 0.476
  3. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.457
  4. Perioperative viral kinetics: new insights or the Emperor's new clothes? Liver Transpl. 2006 Feb; 12(2):194-5.
    View in: PubMed
    Score: 0.250
  5. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis. 2004; 24 Suppl 2:79-88.
    View in: PubMed
    Score: 0.217
  6. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis. 2003 Aug; 7(3):585-602.
    View in: PubMed
    Score: 0.210
  7. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation. 2019 04; 103(4):733-746.
    View in: PubMed
    Score: 0.156
  8. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
    View in: PubMed
    Score: 0.136
  9. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
    View in: PubMed
    Score: 0.134
  10. Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. Gastroenterology. 2016 10; 151(4):633-636.e3.
    View in: PubMed
    Score: 0.129
  11. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
    View in: PubMed
    Score: 0.123
  12. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.120
  13. How important is acute cellular rejection? Liver Transpl. 2013 Nov; 19 Suppl 2:S9-13.
    View in: PubMed
    Score: 0.107
  14. Introduction to the genetics and biology of interleukin-28B. Hepatology. 2012 Jul; 56(1):361-6.
    View in: PubMed
    Score: 0.098
  15. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44.
    View in: PubMed
    Score: 0.095
  16. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44.
    View in: PubMed
    Score: 0.095
  17. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006 Sep; 12(9):1381-9.
    View in: PubMed
    Score: 0.065
  18. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004 Sep; 10(9):1120-30.
    View in: PubMed
    Score: 0.057
  19. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl. 2003 Nov; 9(11):S58-62.
    View in: PubMed
    Score: 0.054
  20. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.053
  21. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002 Oct 15; 35(8):974-81.
    View in: PubMed
    Score: 0.050
  22. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
    View in: PubMed
    Score: 0.048
  23. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology. 2000 Nov; 32(5):1125-30.
    View in: PubMed
    Score: 0.043
  24. Genotype 1b and severity of posttransplant recurrence of hepatitis C infection- unconvictable felon or wrongly accused? Liver Transpl. 2000 Mar; 6(2):243-5.
    View in: PubMed
    Score: 0.041
  25. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol. 2000 Mar; 13(3):229-37.
    View in: PubMed
    Score: 0.041
  26. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology. 2019 06; 69(6):2381-2395.
    View in: PubMed
    Score: 0.039
  27. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
    View in: PubMed
    Score: 0.039
  28. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998 Sep; 28(3):823-30.
    View in: PubMed
    Score: 0.037
  29. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
    View in: PubMed
    Score: 0.036
  30. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017 Nov; 17(11):2790-2802.
    View in: PubMed
    Score: 0.034
  31. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
    View in: PubMed
    Score: 0.031
  32. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014 Sep 17; 6(254):254ra129.
    View in: PubMed
    Score: 0.028
  33. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.023
  34. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep; 44(8):e178-85.
    View in: PubMed
    Score: 0.021
  35. Clinical significance of TT virus infection in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Oct; 94(10):3020-7.
    View in: PubMed
    Score: 0.010
  36. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999 Apr; 29(4):1220-6.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.